[1]陈智鸿王莉林丽瑜李彩凤林雪萍谢起雯林琳邱珊芳滕杰.2022年度厦门市肾病专业质量控制数据分析[J].中国卫生质量管理,2023,30(07):18-23.[doi:10.13912/j.cnki.chqm.2023.30.7.05 ]
 CHEN Zhihong,WANG Li,LIN Liyu.Analysis of Quality Control Data of Nephrology in Xiamen in 2022[J].Chinese Health Quality Management,2023,30(07):18-23.[doi:10.13912/j.cnki.chqm.2023.30.7.05 ]
点击复制

2022年度厦门市肾病专业质量控制数据分析

参考文献/References:

[1]WEBSTER AC, NAGLER EV, MORTON RL, et al. Chronic Kidney Disease[J]. Lancet, 2017, 389(10075): 1238-1252. [2]COLLABORATION G, TRAN K, YAMADA T. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017[J]. Lancet, 2020, 395(10225): 709-733. [3]SHLIPAK MG, TUMMALAPALLI SL, BOULWARE LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference[J]. Kidney Int, 2021, 99(1): 34-47. [4]上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查、诊断及防治指南(2022年版)[J]. 中华肾脏病杂志, 2022, 38(5): 453-464. [5]国家卫生健康委医政医管局.2021年国家医疗质量安全改进目标[J]. 中国卫生质量管理, 2021, 28(4): 15. [6]陈香美.血液净化标准操作规程(2021版)[M].北京:人民卫生出版社,2021:11. [7]陈香美.腹膜透析标准操作规程[M].北京:人民军医出版社,2011:4. [8]WEINHANDL ED, SAFFER TL, ARAGON M. Hidden costs associated with conversion from peritoneal dialysis to hemodialysis[J]. Kidney360, 2022, 3(5): 883-890. [9]陈 彬, 孙承斌, 周建波, 等. 3种不同腹膜透析置管手术方式的对比研究[J]. 中华危重病急救医学, 2021, 33(9): 1084-1087. [10]BELLO AK, ALRUKHAIMI M, ASHUNTANTANG GE, et al. Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action[J]. Kidney Int Suppl (2011), 2017, 7(2): 122-129. [11]SEE EJ, JAYASINGHE K, GLASSFORD N, et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure[J]. Kidney Int, 2019, 95(1): 160-172.[12]DE BOER IH, KHUNTI K, SADUSKY T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: Improving Global Outcomes (KDIGO)[J]. Diabetes Care, 2022, 45(12): 3075-3090. [13]中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏病防治指南(2021年版)[J]. 中华糖尿病杂志, 2021, 13(8): 762-784. [14]PENFOLD RS, PRENDECKI M, MCADOO S, et al. Primary IgA nephropathy: current challenges and future prospects[J]. Int J Nephrol Renovasc Dis, 2018, 11: 137-148. [15]INKER LA, HEERSPINK HJL, TIGHIOUART H, et al. Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis[J]. Am J Kidney Dis, 2021, 78(3): 340-349. [16]DISEASE K, OUTCOMES IG, GROUP G. KDIGO 2021 Clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S): S1-S276.

更新日期/Last Update: 2023-07-15
版权所有© 2015 《中国卫生质量管理》杂志编辑部
陕ICP备20003462号-1
地 址:西安市友谊西路256号; 邮编:710068 ;电话:029-85214975(传真) 029-85253261转2494
技术支持:西安三才科技实业有限公司 029-88222991